Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · May 19, 2026, 7:57 PM
Frekil - Real-World Evidence Infrastructure Regulatory-grade RWE in minutes, not months
Unknown
Verified facts
HTTP 404
HTTP 404
HTTP 404
HTTP 404
HTTP 404
HTTP 404
Nexus score momentum
More runs will build history.
Latest momentum signal per category. Expand a card to inspect raw payloads.
Source types found
Strongest / recent news-style rows
About Frekil
About / company · Mon, May 11, 08:59 AM · confidence 90%high quality
https://www.frekil.com/company/about/Newest first · 14 event(s)
Source: About / company
Frekil is the real-world evidence infrastructure for life sciences. We convert raw clinical data into regulatory-grade evidence in minutes. YC-backed.
Source: Blog / news
RWE timelines are not driven by the final statistical model. The delay comes from protocol specificity, data access, fit-for-purpose checks, cohort logic, and evidence packaging.
Source: Blog / news
Many pharma teams have tried generic AI for RWE and hit the same wall: fluent outputs without enough trust. Here is how Frekil thinks about what LLMs should and should not do.
Source: Blog / news
A practical guide to where RWE fits across discovery, trial design, study execution, regulatory strategy, launch, market access, and life-cycle management - and what can still go wrong.
Source: Blog / news
A plain-English technical guide to propensity scores for survival RWE, using a post-MI statin example to explain matching, weighting, estimands, survival curves, balance checks, and sensitivity analysis.
Source: Blog / news
FDA leaders are signaling that one strong pivotal trial plus confirmatory evidence should become the default approval path. That makes real-world evidence an earlier, more strategic part of development.
Source: Blog / news
External controls can help rare disease and oncology teams answer questions that a conventional randomized trial cannot always reach. The hard part is proving that the comparison is fair.
Source: Blog / news
A practical walkthrough of causal inference for RWE: why naive comparisons fail, how DAGs clarify assumptions, and how target trial emulation turns messy data into a credible study design.
Source: Blog / news
A treatment can clear regulatory review and still face coverage friction. Real-world evidence helps answer the value, affordability, and effectiveness questions payers and HTA bodies actually decide on.
Source: Blog / news
Essays on real-world evidence strategy, RWE methodology, and what we are learning while building the evidence infrastructure layer for life sciences.
Source: Blog / news
Essays on real-world evidence strategy, RWE methodology, and what we are learning while building the evidence infrastructure layer for life sciences.
Source: Homepage
Regulatory-grade RWE in minutes, not months. AI writes the code; your clinical data never touches a model. Built for pharma, biotech, and CRO RWE teams.
Source: Social (linked from site)
Frekil (YC P25) | LinkedIn Skip to main content LinkedIn Top Content People Learning Jobs Games Sign in Join
Source: Social (linked from site)
Something went wrong, but don’t fret — let’s give it another shot.Try again Some privacy related extensions may cause issues on x.com. Please disable them and try again.
1 row(s)
Source name: Homepage
Regulatory-grade RWE in minutes, not months. AI writes the code; your clinical data never touches a model. Built for pharma, biotech, and CRO RWE teams.
https://www.frekil.com/1 row(s)
Source name: About / company
Frekil is the real-world evidence infrastructure for life sciences. We convert raw clinical data into regulatory-grade evidence in minutes. YC-backed.
https://www.frekil.com/company/about/2 row(s)
Source name: Social (linked from site)
Frekil (YC P25) | LinkedIn Skip to main content LinkedIn Top Content People Learning Jobs Games Sign in Join
https://www.linkedin.com/company/frekilSource name: Social (linked from site)
Something went wrong, but don’t fret — let’s give it another shot.Try again Some privacy related extensions may cause issues on x.com. Please disable them and try again.
https://x.com/frekil_ai10 row(s)
Source name: Blog / news
RWE timelines are not driven by the final statistical model. The delay comes from protocol specificity, data access, fit-for-purpose checks, cohort logic, and evidence packaging.
https://www.frekil.com/blog/why-rwe-studies-take-18-months/Source name: Blog / news
Many pharma teams have tried generic AI for RWE and hit the same wall: fluent outputs without enough trust. Here is how Frekil thinks about what LLMs should and should not do.
https://www.frekil.com/blog/why-rwe-needs-multi-agent-ai/Source name: Blog / news
A practical guide to where RWE fits across discovery, trial design, study execution, regulatory strategy, launch, market access, and life-cycle management - and what can still go wrong.
https://www.frekil.com/blog/rwe-opportunities-challenges-drug-development/Source name: Blog / news
A plain-English technical guide to propensity scores for survival RWE, using a post-MI statin example to explain matching, weighting, estimands, survival curves, balance checks, and sensitivity analysis.
https://www.frekil.com/blog/propensity-score-methods-survival-outcomes-rwe/Source name: Blog / news
FDA leaders are signaling that one strong pivotal trial plus confirmatory evidence should become the default approval path. That makes real-world evidence an earlier, more strategic part of development.
https://www.frekil.com/blog/fda-rwe-framework-what-it-means/Source name: Blog / news
External controls can help rare disease and oncology teams answer questions that a conventional randomized trial cannot always reach. The hard part is proving that the comparison is fair.
https://www.frekil.com/blog/external-controls-rwe-clinical-development/Source name: Blog / news
A practical walkthrough of causal inference for RWE: why naive comparisons fail, how DAGs clarify assumptions, and how target trial emulation turns messy data into a credible study design.
https://www.frekil.com/blog/causal-inference-real-world-data-propensity-scores/Source name: Blog / news
A treatment can clear regulatory review and still face coverage friction. Real-world evidence helps answer the value, affordability, and effectiveness questions payers and HTA bodies actually decide on.
https://www.frekil.com/blog/approval-isnt-access-rwe-payers/Source name: Blog / news
Essays on real-world evidence strategy, RWE methodology, and what we are learning while building the evidence infrastructure layer for life sciences.
https://www.frekil.com/blog/Source name: Blog / news
Essays on real-world evidence strategy, RWE methodology, and what we are learning while building the evidence infrastructure layer for life sciences.
https://www.frekil.com/blogSource name: Blog / news
Randomized trials remain essential, but they leave major gaps around real-world effectiveness, patient variation, and value. Real-world evidence is how teams close them.
https://www.frekil.com/blog/rcts-vs-rwe-what-each-one-actually-tells-you/Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.